Arcturus Extends Cash Runway to Q2 2028, Initiates 12-Week CF Study with 10mg Dose
Arcturus extended its cash runway into the second quarter of 2028, reflecting robust financial management. The company plans a 12-week Phase 2 trial of ARCT-032 at a 10mg dose in cystic fibrosis patients, incorporating lung clearance index, high-resolution CT, spirometric stability criteria and quality-of-life endpoints.
1. Extended Cash Runway Through Q2 2028
Arcturus has secured funding to support operations through the second quarter of 2028, underscoring disciplined cash management and extended financial visibility. This runway covers ongoing research programs, potential regulatory activities and general corporate expenses without immediate need for additional financing.
2. Phase 2 ARCT-032 Trial Design
The upcoming 12-week study of ARCT-032 in cystic fibrosis will enroll patients at a 10mg dose, selected based on early efficacy signals. It will require stable baseline lung function, use lung clearance index via multiple breath washout for sensitivity, include high-resolution CT scans for airway assessment and track patient quality-of-life metrics.